Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II docetaxel + carboplatin as second-line treatment in refractory or relapsed small cell lung cancer
2006-004847-47Phase 2Active
- Sponsor
- Jeroen Bosch Hospital
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and carboplatin in small cell lung cancer (SCLC), sponsored by Jeroen Bosch Hospital. Primary endpoint: Response rate. Started Apr 2007; status: active.
02
Drugs
docetaxelcarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-004847-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004847-47.